Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients

BACKGROUND AND AIM: Sarcopenia has received much attention as a poor prognostic factor in various fields, and has also been reported to worsen prognosis in patients with hepatocellular carcinoma (HCC) treated with sorafenib or lenvatinib (LEN). Atezolizumab/bevacizumab (ATZ/BEV) is recommended as fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Toshida, Katsuya, Itoh, Shinji, Tomiyama, Takahiro, Morinaga, Akinari, Kosai, Yukiko, Tomino, Takahiro, Kurihara, Takeshi, Nagao, Yoshihiro, Morita, Kazutoyo, Harada, Noboru, Yoshizumi, Tomoharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260215/
https://www.ncbi.nlm.nih.gov/pubmed/35822124
http://dx.doi.org/10.1002/jgh3.12777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260215/
https://www.ncbi.nlm.nih.gov/pubmed/35822124
http://dx.doi.org/10.1002/jgh3.12777

Ejemplares similares